Univest
Univest
  • Markets

Omkar Speciality Chemicals Analyst Review May 2026

  • May 19, 2026
  • Posted by: Ankit Jaiswal
  • Category: News
No Comments
Omkar Speciality Chemicals Analyst Review

This Omkar Speciality Chemicals analyst review for May 2026 covers the key data investors need for OMKAR at its current price of Rs 188. Omkar Speciality Chemicals (NSE: OMKAR) is a specialty chemicals company with a market capitalisation of approximately Rs 800 crore, manufacturing bromine compounds, iodine derivatives, and pharmaceutical intermediates. The analyst consensus target of Rs 225 implies meaningful upside, and this Omkar Speciality Chemicals analyst review examines technical levels, business segments, valuation, and key risks for OMKAR through FY27.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Omkar Speciality Chemicals Company Snapshot May 2026
  • Analyst Insight in This Omkar Speciality Chemicals Analyst Review
  • Technical Analysis in This Omkar Speciality Chemicals Analyst Review
  • Key Support and Resistance Levels
  • Business Segment Analysis
    • Iodine and Bromine Derivatives (Core Business)
    • Pharmaceutical Intermediates and APIs
    • Specialty Chemicals for Regulated Markets
  • Valuation in This Omkar Speciality Chemicals Analyst Review
  • Trade Outlook for Omkar Speciality Chemicals
  • Key Risks for Omkar Speciality Chemicals in FY27
  • Conclusion: Omkar Speciality Chemicals Analyst Review Verdict for 2026
  • Frequently Asked Questions: Omkar Speciality Chemicals Analyst Review 2026
    • What is the analyst target for Omkar Speciality Chemicals in 2026?
    • Is Omkar Speciality Chemicals a good investment at Rs 188?
    • What is Omkar Speciality Chemicals’s 52-week high and low?
    • What are the key risks for Omkar Speciality Chemicals?
    • Where can I track live data for Omkar Speciality Chemicals?

Omkar Speciality Chemicals Company Snapshot May 2026

Omkar Speciality Chemicals’ iodine compounds (for X-ray contrast media), bromine derivatives (flame retardants), and pharma intermediates serve global regulated markets. China-plus-one sourcing shifts benefit Indian specialty chemical manufacturers. The table below summarises the key data referenced in this Omkar Speciality Chemicals analyst review.

Parameter Value
NSE Ticker OMKAR
Sector Specialty Chemicals – Pharma Intermediates
CMP (May 2026) Rs 188
52 Week High Rs 278
52 Week Low Rs 145
Market Cap Rs 800 Crore
Trailing P/E NAx
Analyst Consensus Target Rs 225
Bull Case Target Rs 290
Bear Case Target Rs 140

Analyst Insight in This Omkar Speciality Chemicals Analyst Review

Senior Research Analyst Ankit Jaiswal flags Omkar Speciality Chemicals as a stock to watch in May 2026. At Rs 188, Ankit Jaiswal identifies key support in the Rs 148 to Rs 179 band and resistance near Rs 199. He suggests watching Omkar Speciality Chemicals for a potential move toward Rs 225, subject to Specialty Chemicals – Pharma Intermediates sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Omkar Speciality Chemicals analyst review and does not constitute a trade recommendation.

Technical Analysis in This Omkar Speciality Chemicals Analyst Review

At Rs 188, OMKAR is trading within its 52-week band of Rs 145 to Rs 278. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 148 to Rs 179 band while resistance is seen in the Rs 199 to Rs 206 zone. A sustained move above Rs 199 could open the path toward the analyst consensus target of Rs 225 as outlined in this Omkar Speciality Chemicals analyst review.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

  • Support Zone: Rs 148 to Rs 179 – investors tracking this Omkar Speciality Chemicals analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for OMKAR.
  • Resistance Zone: Rs 199 to Rs 206 – a sustained close above Rs 199 would be a positive breakout signal worth flagging in this Omkar Speciality Chemicals analyst review.
  • Medium-Term Target: The analyst consensus of Rs 225 represents the base-case upside scenario in this Omkar Speciality Chemicals analyst review.

Business Segment Analysis

Iodine and Bromine Derivatives (Core Business)

This is the primary revenue and margin driver for Omkar Speciality Chemicals, directly supporting the earnings trajectory toward the consensus target of Rs 225.

Pharmaceutical Intermediates and APIs

This segment adds scale and diversification to Omkar Speciality Chemicals’s business model and is a meaningful EPS contributor through FY27 and FY28.

Specialty Chemicals for Regulated Markets

This represents the medium-term growth frontier for Omkar Speciality Chemicals and a key re-rating catalyst over the next 12 to 24 months.

Valuation in This Omkar Speciality Chemicals Analyst Review

At Rs 188, Omkar Speciality Chemicals trades at a trailing P/E of NAx. This Omkar Speciality Chemicals analyst review presents three scenarios: a bull case of Rs 290 on strong earnings delivery and sector tailwinds, a base case of Rs 225 at analyst consensus, and a bear case of Rs 140 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Omkar Speciality Chemicals analyst review.

Scenario Target Price Key Condition
Bull Case Rs 290 Strong earnings delivery and sector re-rating
Base Case (Consensus) Rs 225 Moderate growth, analyst consensus estimate
Bear Case Rs 140 Earnings miss or macro headwinds

Trade Outlook for Omkar Speciality Chemicals

Based on the technical and fundamental analysis in this Omkar Speciality Chemicals analyst review, investors might watch OMKAR near the support zone of Rs 148 to Rs 179 for potential opportunities. A flag above Rs 199 could suggest improving momentum toward Rs 225. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Omkar Speciality Chemicals in FY27

A well-rounded Omkar Speciality Chemicals analyst review must assess downside risks. Key risks for Omkar Speciality Chemicals include a macro slowdown affecting Specialty Chemicals – Pharma Intermediates sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in OMKAR.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Omkar Speciality Chemicals Analyst Review Verdict for 2026

This Omkar Speciality Chemicals analyst review concludes that at Rs 188, OMKAR offers a defined risk-reward with a consensus target of Rs 225. The 52-week range of Rs 145 to Rs 278 provides context on the current entry point. Use this Omkar Speciality Chemicals analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on OMKAR.

Frequently Asked Questions: Omkar Speciality Chemicals Analyst Review 2026

What is the analyst target for Omkar Speciality Chemicals in 2026?

The analyst consensus target is Rs 225, with a bull case of Rs 290 and a bear case of Rs 140. This Omkar Speciality Chemicals analyst review recommends monitoring Q1 FY27 earnings for confirmation.

Is Omkar Speciality Chemicals a good investment at Rs 188?

At Rs 188 with a P/E of NAx and a consensus target of Rs 225, this Omkar Speciality Chemicals analyst review is constructive for medium to long-term investors in the Specialty Chemicals – Pharma Intermediates sector. Always consult a SEBI-registered advisor before investing.

What is Omkar Speciality Chemicals’s 52-week high and low?

The 52-week high is Rs 278 and the 52-week low is Rs 145. At Rs 188, OMKAR is positioned within this range as detailed in this Omkar Speciality Chemicals analyst review.

What are the key risks for Omkar Speciality Chemicals?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Specialty Chemicals – Pharma Intermediates sector, all assessed in this Omkar Speciality Chemicals analyst review.

Where can I track live data for Omkar Speciality Chemicals?

Track Omkar Speciality Chemicals’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Omkar Speciality Chemicals analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.



News
Author: Ankit Jaiswal
Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.

Leave a Reply Cancel reply